Page 1 | Search Results | Hematology, ASH Education Program

1-7 of 7

Sort by

Sort Order Select

Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.

https://doi.org/10.1182/asheducation-2017.1.480

Published: 2017

Journal Articles

Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease

Julien Haroche, Oussama Abla

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 571–578.

https://doi.org/10.1182/asheducation.V2015.1.571.3916289

Published: 2015

Journal Articles

Viral-Associated Immune Thrombocytopenic Purpura

Howard A. Liebman

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 212–218.

https://doi.org/10.1182/asheducation-2008.1.212

Published: 2008

Journal Articles

Pathophysiologic Mechanisms in Acquired Aplastic Anemia

Neal S. Young

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 72–77.

https://doi.org/10.1182/asheducation-2006.1.72

Published: 2006

Journal Articles

Chronic Granulomatous Disease and Other Disorders of Phagocyte Function

Mary C. Dinauer

Hematology Am Soc Hematol Educ Program (2005) 2005 (1): 89–95.

https://doi.org/10.1182/asheducation-2005.1.89

Published: 2005

Journal Articles

A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment

Thomas C. Pearson, Maria Messinezy, Nigel Westwood, Anthony R. Green, Anthony J. Bench, Anthony R. Green, Brian J.P. Huntly, Elizabeth P. Nacheva, Tiziano Barbui, Guido Finazzi

Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 51–68.

https://doi.org/10.1182/asheducation.V2000.1.51.51

Published: 2000

Journal Articles

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies

Hagop Kantarjian, Junia V. Melo, Sante Tura, Sergio Giralt, Moshe Talpaz

Hematology Am Soc Hematol Educ Program (2000) 2000 (1): 90–109.

https://doi.org/10.1182/asheducation.V2000.1.90.90

Published: 2000

NARROW

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease

Viral-Associated Immune Thrombocytopenic Purpura

Pathophysiologic Mechanisms in Acquired Aplastic Anemia

Chronic Granulomatous Disease and Other Disorders of Phagocyte Function

A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies

ASH Publications

American Society of Hematology

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease

Viral-Associated Immune Thrombocytopenic Purpura

Pathophysiologic Mechanisms in Acquired Aplastic Anemia

Chronic Granulomatous Disease and Other Disorders of Phagocyte Function

A Polycythemia Vera Update: Diagnosis, Pathobiology, and Treatment

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only